Skip to content
Log in
Sponsored AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI AI AM CLAUDE, A Beginner's Guide: Learn the basics of working with AI

Author

M. Lebwohl

h-index 26 View on Semantic Scholar

We have 3 of 204 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials

Background Icotrokinra, a targeted oral peptide that precisely blocks the interleukin-23 receptor, is approved to treat adult and pediatric (≥12 years, ≥40 kg) patients with moderate-to-severe plaque psoriasis (PsO). Objective Assess psoriatic arthritis (PsA)–specific outcomes through Week (W) 16 in a subgroup of phase...

I. McInnes, L. Stein-Gold, R. Bissonnette et al. · 0 citations
Open access Oct 2026

Early Time Course of Symptom Improvement With Remibrutinib in Chronic Spontaneous Urticaria: Pooled Post Hoc Analyses of the REMIX-1/2 Phase 3 Studies.

We undertook a post hoc, sponsor‐funded analysis of data from two recent clinical trials in CSU. Remibrutinib numerically improved CSU symptoms at 12 h; meaningful effects persisted from Day‐2 through Week‐52.

Gordon Sussman, N. Chapman-Rothe, Tao Ding et al. · 0 citations
Open access Oct 2026

Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action Study.

Data confirm a role for the IFN-γ-CXCL10 axis in vitiligo pathogenesis and suggest that reductions in CXCL10 expression correlate with clinical repigmentation with ruxolitinib cream.

T. Passeron, M. Lebwohl, C. Lynde et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.